HOUSTON, TX --(Marketwired - April 26, 2018) - Moleculin Biotech, Inc., (
The Global Academic Programs ("GAP") 2018 is being hosted in Stockholm, Sweden from May 15 to 17, 2018. The annual GAP Conference provides a forum for faculty from MD Anderson and its Sister Institutions to develop collaborations and exchange research results and ideas. Sessions are formed around topics of interest to the members of the Sister Institution Network. The GAP 2018 Conference is being sponsored by a prestigious list of major pharmaceutical companies, including Roche, Bayer, Bristol-Meyers Squibb, AstraZeneca, Novartis, Merck and Pfizer.
"We are eager to share our important findings with regard to WP1066 and its effects on pancreatic cancer that include the ability to suppress activation of STAT3 in vitro and in vivo and simultaneously producing strong anticancer effects in this most deadly type of cancer," commented Dr. Waldemar Priebe, Chair of Moleculin's Scientific Advisory Board. "In addition to pancreatic cancer, WP1066 appears to produce significant anticancer effects in animal models of other difficult to treat tumors, including brain cancers like glioblastoma. Moleculin has already announced an approved IND for brain tumors. We hope our continuation of the in vivo evaluation of WP1066 in different tumor models will provide a strong basis for the initiation of additional clinical trials in the future."
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on discoveries made at M.D. Anderson Cancer Center. Our clinical stage drugs are Annamycin, an anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, and WP1066, an immuno-stimulating STAT3 inhibitor targeting brain tumors, pancreatic cancer and AML. We are also engaged in preclinical development of additional drug candidates, including additional STAT3 inhibitors and compounds targeting the metabolism of tumors.
For more information about the Company, please visit http://www.moleculin.com .
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing of any clinical trials for WP1066 and whether future evaluation in different tumor models will provide a basis for additional clinical trials. These statements relate to future events, future expectations, plans and prospects. Although Moleculin Biotech believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin Biotech has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. "Risk Factors" in our most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Contacts Joe Dorame, Robert Blum or Joe Diaz Lytham Partners, LLC 602-889-9700 mbrx@lythampartners.com
